e-Profile Login and ID Quick Search
Studies Confirm New Heparin Monograph Results in Less Potent Drug
Heparin Sodium, USP (heparin) made under the new United States Pharmacopeia (USP) Monograph has approximately 10% less anticoagulant activity compared to heparin prepared using the previous USP Monograph, as confirmed by FDA-commissioned laboratory studies. FDA recommends that health care professionals exercise clinical judgment in determining the dose of heparin for a patient and consider the clinical circumstances where the potency decrease may require dosage adjustments and more frequent monitoring. More information is available in an FDA Drug Safety Communication.
